SO010PATIROMER PROTECTED AGAINST RECURRENT HYPERKALEMIA FOR UP TO 52 WEEKS IN PATIENTS WITH DIABETIC KIDNEY DISEASE (DKD) RECEIVING COMBINED RAAS INHIBITOR THERAPY
Introduction and Aims: Renin-angiotensin-aldosterone system inhibitors (RAASi), such as angiotensin-converting-enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), are preferred first-line drugs in high-risk patients (pts) with diabetes. Dual therapy (D) with an ACE inhibitor and an ARB, or combined therapy in which an ACE and/or ARB is used with a mineralocorticoid antagonist (C), may have greater cardiorenal benefit versus monotherapy in select patients with DKD, and in patients with heart failure. However, the use of D or C RAASi therapy is frequently limited by hyperkalemia (HK).